Sugi Predict

Sugi Predict / Compounds / SCHEMBL4939718

SCHEMBL4939718

SCHEMBL4939718

COC(=O)C1CCCC(=O)N1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 1/20 0.42
▸ LMNA P02545 1/20 0.40
▸ GAA P10253 1/20 0.38
▸ HDAC3 O15379 7/20 0.37
▸ HDAC11 Q96DB2 7/20 0.37
▸ HDAC6 Q9UBN7 7/20 0.37
▸ HDAC1 Q13547 6/20 0.37
▸ HDAC2 Q92769 6/20 0.37
▸ HDAC10 Q969S8 6/20 0.37
▸ HDAC8 Q9BY41 6/20 0.37
▸ THRB P10828 1/20 0.37
▸ ABL1 P00519 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ CHRNB2 P17787 1/20 0.35
▸ CHRNB4 P30926 1/20 0.35
▸ CHRNA3 P32297 1/20 0.35
▸ CHRNA7 P36544 1/20 0.35
▸ CHRNA4 P43681 1/20 0.35
▸ NCOR2 Q9Y618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4939720 1.00 KMT2A (0.42) KMT2ALMNAGAAHDAC3HDAC11
SCHEMBL5026447 1.00 KMT2A (0.42) KMT2ALMNAGAAHDAC3HDAC11
SCHEMBL6818436 0.95 KMT2A (0.41) KMT2ALMNAGAAHDAC3HDAC11
SCHEMBL3954018 0.95 KMT2A (0.41) KMT2ALMNAGAAHDAC3HDAC11
SCHEMBL6810038 0.95 KMT2A (0.41) KMT2ALMNAGAAHDAC3HDAC11
SCHEMBL475421 0.89 LMNA (0.48) KMT2ALMNAGAAPOLBCNR1
SCHEMBL78947 0.89 LMNA (0.48) KMT2ALMNAGAAPOLBCNR1
SCHEMBL317779 0.89 LMNA (0.48) KMT2ALMNAGAAPOLBCNR1
SCHEMBL24537183 0.84 HDAC3 (0.38) KMT2ALMNAGAAHDAC3HDAC11
Methylene Chloride SCHEMBL28127317 0.82 LMNA (0.47) KMT2ALMNAGAAPOLBCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4648853-A1 TARGETED DEGRADATION OF VAV1 Monte Rosa Therapeutics AG (CH) 2025-11-19 — — EP disclosed
US-20250205219-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS AG (CH) 2025-06-26 — — US disclosed
US-12257247-B2 Targeted degradation of VAV1 MONTE ROSA THERAPEUTICS AG (CH) 2025-03-25 — — US disclosed
US-20250090540-A1 PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2025-03-20 — — US disclosed
US-20240285604-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS AG (CH) 2024-08-29 — — US disclosed
WO-2024151547-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS, INC. (US) 2024-07-18 — — WO disclosed
WO-2024151547-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS, INC. (US) 2024-07-18 — — WO disclosed
EP-4399196-A1 PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF Relay Therapeutics, Inc. (US) 2024-07-17 — — EP disclosed
CN-118201896-A PI 3K-alpha inhibitors and methods of use thereof 传达治疗有限公司 2024-06-14 — — CN disclosed
EP-3455224-B1 SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-3(2H)-ONES AND 2,5,6,7-TETRAHYDRO-3H-PYRROLO[2,1-C][1,2,4]TRIAZOL-3-ONES, AND USE THEREOF BAYER AG (DE) 2024-03-27 — — EP disclosed
EP-1585729-A1 2-PIPERIDONE DERIVATIVES AS PROSTAGLANDIN AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2005-10-19 — — EP disclosed
EP-1373269-B1 JUN KINASE INHIBITORS EISAI CO LTD (JP) 2005-06-08 — — EP disclosed
EP-1511749-A1 NOVEL INTERLEUKIN-1BETA CONVERTING ENZYME INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2005-03-09 — — EP disclosed
US-20040235864-A1 Jun kinase inhibitors EISAI R & D MANAGEMENT CO., LTD. (JP) 2004-11-25 — — US disclosed
WO-2004063158-A1 2-PIPERIDONE DERIVATIVES AS PROSTAGLANDIN AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2004-07-29 — — WO disclosed
US-20040142969-A1 2-Piperidone derivatives as prostaglandin agonists ROCHE PALO ALTO LLC 2004-07-22 — — US disclosed
US-20040014753-A1 Novel interleukin-1beta converting enzyme inhibitors THE PROCTER & GAMBLE COMPANY 2004-01-22 — — US disclosed
EP-1373269-A1 JUN KINASE INHIBITORS Eisai Co., Ltd. (JP) 2004-01-02 — — EP disclosed
WO-2003104231-A1 NOVEL INTERLEUKIN-1β CONVERTING ENZYME INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2003-12-18 — — WO disclosed
WO-2002081475-A1 JUN KINASE INHIBITORS EISAI CO., LIMITED (JP) 2002-10-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240285604-A1 TARGETED DEGRADATION OF VAV1 VAV1, KRAS, CBL KMT2A 1159/4885LMNA 4340/4885GAA 2363/4885
US-12257247-B2 Targeted degradation of VAV1 VAV1, KRAS, CBL KMT2A 1159/4885LMNA 4340/4885GAA 2363/4885
US-20040142969-A1 2-Piperidone derivatives as prostaglandin agonists PTGER1, PTGER2, PTGER4 KMT2A 3116/4885LMNA 1940/4885GAA 4538/4885
US-20040235864-A1 Jun kinase inhibitors NFKBIA, JUN, AIFM1 KMT2A 3298/4885LMNA 2363/4885GAA 2165/4885
US-20250090540-A1 PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF PIK3CA, PIK3CB, PIK3CD KMT2A 2974/4885LMNA 2874/4885GAA 141/4885
US-20250205219-A1 TARGETED DEGRADATION OF VAV1 VAV1, KRAS, CBL KMT2A 1159/4885LMNA 4340/4885GAA 2363/4885
US-20040014753-A1 Novel interleukin-1beta converting enzyme inhibitors IL1B, IL1RN, IL1R1 KMT2A 3415/4885LMNA 1962/4885GAA 2986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.